Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
3B Blackbio DX Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
24 Sept 2026
3B Blackbio DX Q1 FY27 earnings call: Revenue & Margins | Arthneeti
Q1 FY27
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
24 Sept 2026
Everest Kanto Cylinder Q1 FY27 earnings call: Revenue & Margins | Arthneeti
Q1 FY27
346 crore, down 10% YoY from Rs. Key concall takeaways from Everest Kanto Cylinder Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q3 FY24 earnings call: Revenue & Margins | Arthneeti
Q3 FY24
82.51 Cr, down 7.06% year-on-year from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q4 FY24 earnings call: Revenue & Margins | Arthneeti
Q4 FY24
97.82 Cr, up 22.11% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q1 FY25 earnings call: Revenue & Margins | Arthneeti
Q1 FY25
122.99 Cr, up 27.26% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q2 FY25 earnings call: Revenue & Margins | Arthneeti
Q2 FY25
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
24 Sept 2026
Themis Medicare Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q1 FY26: Revenue ₹97.58 Cr, PAT ₹14.22 Cr | Arthneeti
Q1 FY26
Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q1 FY26 earnings…
24 Sept 2026
Themis Medicare Q2 FY26: Revenue ₹77.99 Cr, PAT ₹14.29 Cr | Arthneeti
Q2 FY26
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
24 Sept 2026
Themis Medicare Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
90.13 Cr, a 3.9% decline year-on-year from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
24 Sept 2026
Themis Medicare Q4 FY26: Revenue ₹76.53 Cr, PAT ₹8.89 Cr | Arthneeti
Q4 FY26
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
24 Sept 2026
Themis Medicare Q1 FY27: Revenue ₹86.96 Cr, PAT ₹24.61 Cr | Arthneeti
Q1 FY27
Q1 FY27 Net Revenue: ₹86.96 crore . Key concall takeaways from Themis Medicare Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
24 Sept 2026
Gayatri Projects Q4 FY19 earnings call: Revenue & Margins | Arthneeti
Q4 FY19
Q4 FY2019 Revenue: INR 11,511 million vs INR 9,332 million in Q4 FY2018, a 23% YoY increase (Page 9) . Key concall takeaways from Gayatri Projects Ltd's Q4…
24 Sept 2026
Gayatri Projects Q2 FY20 earnings call: Revenue & Margins | Arthneeti
Q2 FY20
Year-on-year (YoY) revenue growth: 14% . Key concall takeaways from Gayatri Projects Ltd's Q2 FY20 earnings call — and how it ranks against sector peers.
24 Sept 2026
Remus Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY). Key concall takeaways…
24 Sept 2026
Remus Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins | Arthneeti
Q4 FY26
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key concall takeaways from Remus Pharmaceuticals Ltd's Q4 FY26…
24 Sept 2026
Kamdhenu Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
191.1 Cr, up 1% YoY from Rs. Key concall takeaways from Kamdhenu Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
24 Sept 2026
Kamdhenu Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
168.8 Cr, down 3% YoY from Rs. Key concall takeaways from Kamdhenu Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
24 Sept 2026